로딩 중…
지수 로딩 중…
우진비앤지
018620· KOSDAQ· Health Care· Pharmaceuticals, Biotechnology & Life Sciences
₩2,600-1.52%
2026-08-04
Financials
Valuation Metrics
우진비앤지's Market Cap is ₩180B. At end of 2025 it was ₩240B. Ranked #2348 of 2,436 in KR market (top 96%), #1569 of 1,649 on KOSDAQ (top 95%), #230 of 234 in Pharmaceuticals, Biotechnology & Life Sciences (top 98%) by Market Cap.
Investment Metrics(as of 2026-08-04)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | 18.03B KRW | KR#2,348/2,436 Sec#230/234 |
| Revenue | 54.75B KRW | KR#1,731/2,436 Sec#119/234 |
| Net Income | -3.89B KRW | KR—/2,436 Sec—/234 |
| Total Assets | 107.36B KRW | KR#1,698/2,436 Sec#137/234 |
| Net Assets | 63.83B KRW | KR#1,709/2,436 Sec#146/234 |
| Employees | 98 | KR#1,634/2,436 Sec#127/234 |
| Value | ||
| P/B | 0.28x | KR#289/2,436 Sec#9/234 |
| P/S | 0.33x | KR#653/2,436 Sec#15/234 |
| EV/EBITDA | 59.73x | KR#1,388/2,436 Sec#93/234 |
| FCF Yield | 5.90% | KR#815/2,436 Sec#40/234 |
| Profitability | ||
| ROE | -6.10% | KR#1,780/2,436 Sec#132/234 |
| ROA | -3.62% | KR#1,814/2,436 Sec#133/234 |
| Op. Margin | 1.10% | KR#1,468/2,436 Sec#106/234 |
| Revenue Growth | -0.11% | KR#1,447/2,436 Sec#139/234 |
| Earnings Growth | -206.24% | KR#1,500/2,436 Sec#98/234 |
| Financial Health | ||
| Debt Ratio | 168.21% | KR#1,418/2,436 Sec#163/234 |
| Total Debt | 28.72B KRW | KR#1,217/2,436 Sec#98/234 |
| FCF | 1.06B KRW | KR#1,139/2,436 Sec#84/234 |
| Cash | 10.87B KRW | KR#1,631/2,436 Sec#125/234 |
| Net Debt/EBITDA | 29.72x | KR#1,477/2,436 Sec#104/234 |
| Performance | ||
| 1Y Return | -35.99% | KR#1,734/2,436 Sec#154/234 |
| 1M Return | 5.69% | KR#436/2,436 Sec#36/234 |
| From 52W High | -40.39% | KR#772/2,436 Sec#55/234 |
| 1Y MDD | -46.11% | KR#751/2,436 Sec#63/234 |
| Trading | ||
| Volume | 19,183 shares | KR#1,880/2,436 Sec#186/234 |
| Foreign Own. | 2.98% | KR—/2,436 Sec—/234 |
| Per Share | ||
| EPS | -308 KRW | KR—/2,436 Sec—/234 |
| BPS | 4,425 KRW | KR#1,544/2,436 Sec#114/234 |
Company Info
동사는 1985년 동물용 의약품 제조 및 판매를 위해 설립되어 2008년 코스닥시장에 상장함. 동물용의약품과 인체원료의약품, 미생물제제, 백신 등을 제조·판매하고 있음. 동사의 종속회사들은 반려동물용 사료 및 간식 제조 사업을 영위함. 최근 반려동물 입양문화가 급속히 확산됨에 따라, 당사는 반려동물의 연령과 건강 상태를 고려한 기능성 간식과 처방식 사료 제품 개발에 주력하고 있음. 우진비앤지는 1985년에 설립되었으며 경기도 화성시에 본사를 두고 있습니다.